Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.63 |
| ▸ | PTGES | O14684 | 4/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 10/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1460938 | 0.90 | ORAI1 (0.64) | ORAI1PTGESCYP2C9DGAT1FFAR1 | |
| SCHEMBL1460119 | 0.90 | ORAI1 (0.77) | ORAI1PTGESCYP2C9LOXL2FFAR1 | |
| SCHEMBL28799266 | 0.84 | ORAI1 (0.61) | ORAI1PTGESCYP2C9DGAT1FFAR1 | |
| SCHEMBL1460101 | 0.84 | ORAI1 (0.59) | ORAI1PTGESCYP2C9FFAR1 | |
| SCHEMBL1458826 | 0.83 | ORAI1 (0.66) | ORAI1DGAT1LOXL2 | |
| SCHEMBL12825958 | 0.82 | ORAI1 (0.57) | ORAI1PTGESCYP2C9FFAR1 | |
| SCHEMBL1459911 | 0.81 | ORAI1 (0.58) | ORAI1PTGESCYP2C9FFAR1 | |
| SCHEMBL1461026 | 0.80 | ORAI1 (0.58) | ORAI1PTGESCYP2C9FFAR1ROCK2 | |
| SCHEMBL1464317 | 0.80 | ORAI1 (0.55) | ORAI1PTGESCYP2C9FFAR1 | |
| SCHEMBL1460840 | 0.79 | ORAI1 (0.54) | ORAI1PTGESCYP2C9FFAR1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480529-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | claimed |
| CN-102574788-A | Indole derivatives as crac modulators | HOFFMANN LA ROCHE | 2012-07-11 | — | — | CN | claimed |
| WO-2011036130-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | claimed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | claimed |
| EP-2480529-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| CN-102574788-A | Indole derivatives as crac modulators | HOFFMANN LA ROCHE | 2012-07-11 | — | — | CN | disclosed |
| WO-2011036130-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| WO-2011036130-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ORAI1, RYR2, CACNA1E | ORAI1 1/4885PTGES 963/4885CYP2C9 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.